Level C· Early human research exploring benefitsProspective StudyPubMed

Dysfunctional vasculogenesis in adipose-derived stem cells from chronic spinal cord injury patients: implications for autologous cell therapy.

Yang D., Yang L., Chen J., Wang Z., Wang S., Yang J.

Prospective Study on Spinal Cord Injury, Chronic Wound, published in Angiogenesis (2025) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Prospective Study
Journal
Angiogenesis (2025)
Country
Germany
Reported sample size
—
Source database
PubMed
PMID
41071362
DOI
10.1007/s10456-025-10012-w

Abstract (original English)

The recent study by Santos-De-La-Mata et al. (Angiogenesis 28(4): 482025, 2025) provides critical evidence that adipose-derived stem cells (ASCs) from patients with chronic spinal cord injury (SCI) and pressure injuries (PIs) exhibit significantly impaired vasculogenic potential.1 Their comparative analysis revealed deficits in key pro-angiogenic functions, including reduced proliferation, migration, tube formation, and secretion of vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) in SCI/PI-derived ASCs compared to healthy controls. These in vitro findings were corroborated by a diminished capacity to support neovascularization in an in vivo Matrigel plug assay. This cellular dysfunction underscores a fundamental mechanism contributing to refractory wound healing in this patient population and critically challenges the efficacy of autologous ASC-based therapies. This analysis discusses these findings in the context of chronic inflammatory microenvironments and epigenetic regulation,2,3 and explores potential strategies to overcome this impairment, including allogeneic cell sources4,5 and pre-conditioning techniques to rejuvenate patient-derived cells.6 The work of Santos-De-La-Mata et al. establishes a vital foundation for developing more effective, personalized regenerative medicine approaches for complex chronic wounds.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence
AnimalsHumansAdipose TissueCell- and Tissue-Based TherapyChronic DiseaseNeovascularization, PhysiologicSpinal Cord InjuriesStem Cell TransplantationStem CellsTransplantation, Autologous

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research